PINT and Vect-Horus have published a new publication in the Controlled Release Society (Journal of Controlled Release), presenting camelid-derived single-domain antibodies (VHHs) that target a novel epitope of transferrin receptor 1 (TfR1) to deliver therapeutics across the blood-brain barrier.

These cross-reactive VHHs—effective in rodents, primates, and humans—offer a modular platform for next-generation CNS drug delivery.

https://www.sciencedirect.com/science/article/pii/S0168365925009587?via%3Dihub#s0245